Sintilimab |
カタログ番号GC65290 |
シンチリマブ (IBI308) は、PD-1 に結合する完全ヒト IgG4 モノクローナル抗体であり、それによって PD-1 とそのリガンド (PD-L1 および PL-L2) との相互作用をブロックし、その結果、内因性抗腫瘍 T 細胞応答の回復を助けます.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2072873-06-2
Sample solution is provided at 25 µL, 10mM.
Sintilimab (IBI308) is a fully human IgG4 monoclonal antibody that binds to PD-1, thereby blocking the interaction of PD-1 with its ligands (PD-L1 and PL-L2) and consequently helping to restore the endogenous antitumour T-cell response. Sintilimab can be used for the research of classical Hodgkin's lymphoma, non-small cell lung cancer and oesophageal cancer[1].
[1]. Sheridan M Hoy. Sintilimab: First Global Approval Drugs. 2019 Feb;79(3):341-346.
Average Rating: 5
(Based on Reviews and 30 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *